Annotation Detail
Information
- Associated Genes
- CTLA4
- Associated Variants
- CTLA4 UNKNOWN
- Source Database
- MMMP
- Description
- Phase II trial. Eight (10%) of 84 response-assessable patients attained objective antitumor responses. Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. Both phase II regimens generated durable tumor responses. Based on its more favorable safety profile, 15 mg/kg every 3 months was selected for further clinical testing
- MMMP State
- uncharacterized
- MMMP Molecule
- CTLA4
- MMMP Relationship
- sensitivity to
- MMMP Drug
- Tremelimumab
- MMMP Drug Alias
- CTLA4 antibody (antagonist) CP-675,206
- MMMP Model
- 5
- MMMP Reference
- Camacho LH, J Clin Oncol 2009, 27:1075-81
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Tremelimumab | Sensitivity | true |